Որոնման արդյունքները - Judith Schimpf
- Ցուցադրվում են 1 - 4 արդյունքները 4
-
1
Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost Tamara Davidovic, Judith Schimpf, Armin Abbassi-Nik, Richard Stockinger, Hannelore Sprenger-Mähr, Karl Lhotta, Emanuel Zitt
Հրապարակվել է 2021Carta -
2
The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients Emanuel Zitt, Tamara Davidovic, Judith Schimpf, Armin Abbassi-Nik, Beatrix Mutschlechner, Hanno Ulmer, Magdalena Benda, Hannelore Sprenger-Mähr, Thomas Winder, Karl Lhotta
Հրապարակվել է 2021Artigo -
3
Evaluation of Circulating GPC4 in Patients with End-Stage Kidney Disease Axel Muendlein, Eva Maria Brandtner, Judith Schimpf, M Piribauer, Kathrin Geiger, Christine Heinzle, Andreas Leiherer, Heinz Drexel, Otto Freistätter, Ulrich Neyer, Emanuel Zitt
Հրապարակվել է 2025Artigo -
4
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy Aliza Thompson, Kevin Carroll, Lesley A. Inker, Jürgen Floege, Vlado Perkovic, Sonia Boyer‐Suavet, Rupert Major, Judith Schimpf, Jonathan Barratt, Daniel C. Cattran, Barbara S. Gillespie, Annamaria Kausz, Alex Mercer, Heather N. Reich, Brad H. Rovin, Melissa West, Patrick H. Nachman
Հրապարակվել է 2019Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Internal medicine
Medicine
Hemodialysis
Antibody
Coronavirus disease 2019 (COVID-19)
Dialysis
Disease
Endocrinology
Immunology
Infectious disease (medical specialty)
Kidney
Kidney disease
Renal function
Vaccination
Clinical trial
Creatinine
Diabetes mellitus
End stage renal disease
Gastroenterology
Immunogenicity
Intensive care medicine
Liter
Nephropathy
Proteinuria
Seroconversion
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Surrogate endpoint
Urology
Virology